Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue.
Clin Oncol (R Coll Radiol)
; 12(2): 121-3, 2000.
Article
en En
| MEDLINE
| ID: mdl-10853753
ABSTRACT
The case history is presented of a patient with paraplegia caused by progressive spinal cord compression due to bone metastases of a neuroendocrine pulmonary tumour. After failed external radiotherapy, the patient received targeted internal radiotherapy administered as a fractionated treatment with intravenous injections of a total of 7400 MBq/m2 of [90YDOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue. This case history highlights the value of 90Y-DOTATOC in the treatment of neuroendocrine tumours and the importance and possibility of good palliation of neuroendocrine bone metastases.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Paraplejía
/
Compresión de la Médula Espinal
/
Neoplasias de la Columna Vertebral
/
Somatostatina
/
Octreótido
/
Tumores Neuroendocrinos
/
Radiofármacos
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2000
Tipo del documento:
Article